Related Experiment Video
Updated: Mar 29, 2026
07:48
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
13.2K
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer
Robert T Jones1, Kenneth M Felsenstein1, Dan Theodorescu1
1University of Colorado Cancer Center, Aurora, CO, USA; Medical Scientist Training Program, University of Colorado School of Medicine, Aurora, CO, USA.
The Urologic Clinics of North America
|November 29, 2015
Summary
Effective bladder cancer treatment needs new approaches. Identifying patients likely to respond to therapies using predictive biomarkers will improve outcomes in advanced bladder cancer.
Area of Science:
- Urologic oncology
- Molecular biology
- Genetics
Background:
- Clinical management of bladder cancer has remained largely unchanged for over 30 years.
- There is a critical need for improved treatments for advanced bladder cancer.
- Limited prediction of patient response to neoadjuvant therapies hinders their clinical use.
Purpose of the Study:
- To review recent molecular and genetic studies in bladder cancer.
- To highlight promising clinical trials and retrospective studies.
- To discuss emerging trials utilizing predictive biomarkers for personalized therapy.
Main Methods:
- Focus on recent molecular and genetic research findings.
- Analysis of data from clinical trials and retrospective studies.
- Examination of emerging biomarker-driven therapeutic strategies.
Main Results:
- Recent studies show promise in identifying predictive biomarkers for bladder cancer treatment.
- Emerging clinical trials are investigating the efficacy of biomarker-guided therapies.
- Personalized medicine approaches are showing potential to improve treatment response.
Conclusions:
- Predictive genomic and molecular biomarkers are poised to transform bladder cancer treatment.
- Matching patients to therapies based on biomarkers will enhance clinical management.
- The future of urologic oncology involves biomarker-driven precision medicine for bladder cancer.
Keywords:
Bladder cancerClinical trialsImmunotherapyMolecular subtypePersonalized medicinePharmacogenomicsPrecision medicinePredictive biomarkerMore Related Videos
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
01:29Pharmacogenomics: Identification of New Drug Targets
76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:29Pharmacogenetics and Pharmacogenomics: Overview
144
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
144
01:27Pharmacogenetics of Drug Metabolism: Overview
112
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
112
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K